{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T21:12:51Z","timestamp":1786569171644,"version":"build-2736575974"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2018,11,26]],"date-time":"2018-11-26T00:00:00Z","timestamp":1543190400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1038\/s41388-018-0563-y","type":"journal-article","created":{"date-parts":[[2018,11,26]],"date-time":"2018-11-26T15:03:26Z","timestamp":1543244606000},"page":"2320-2336","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["The renin angiotensin system (RAS) mediates bifunctional growth regulation in melanoma and is a novel target for therapeutic intervention"],"prefix":"10.1038","volume":"38","author":[{"given":"Alexander","family":"Renziehausen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hexiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhavya","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynda","family":"Weir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiana Lo","family":"Nigro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Lattanzio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Merlano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Vega-Rioja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"del Carmen Fernandez-Carranco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabil","family":"Hajji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rubeta","family":"Matin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Harwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Van Ren","family":"Sim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"O\u2019Neill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alastair","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Szlosarek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Fleming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Stebbing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3292-4836","authenticated-orcid":false,"given":"Charlotte","family":"Proby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas G.","family":"Tzakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelofer","family":"Syed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Crook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,26]]},"reference":[{"key":"563_CR1","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3410\/M3-8","volume":"3","author":"KT Flaherty","year":"2011","unstructured":"Flaherty KT. Next generation therapies change the landscape in melanoma. F1000 Med Rep. 2011;3:8.","journal-title":"F1000 Med Rep"},{"key":"563_CR2","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","volume":"364","author":"PB Chapman","year":"2012","unstructured":"Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2012;364:2507\u201316.","journal-title":"N Engl J Med"},{"key":"563_CR3","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1056\/NEJMoa1203421","volume":"367","author":"KT Flaherty","year":"2012","unstructured":"Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012;367:107\u201314.","journal-title":"N Engl J Med"},{"key":"563_CR4","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.1158\/1078-0432.CCR-14-1650","volume":"21","author":"RJ Sullivan","year":"2015","unstructured":"Sullivan RJ, Flaherty KT. New strategies in melanoma: entering the era of combinatorial therapy. Clin Cancer Res. 2015;21:2424\u201335.","journal-title":"Clin Cancer Res"},{"key":"563_CR5","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.ejca.2011.09.018","volume":"48","author":"Z Hanaizi","year":"2012","unstructured":"Hanaizi Z, Van Zwieten-Boot B, Calvo G, Lopez AS, Van Dartel M, Camarero J, et al. The European Medicines Agency review of ipilimumab (Yervoy) for the treatment of advanced (unresectable or metastatic) melanoma in adults who have received prior therapy: summary of the scientific assessment of the Committee for Medicinal Products for Human Use. Eur J Cancer. 2012;48:237\u201342.","journal-title":"Eur J Cancer"},{"key":"563_CR6","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1053\/j.seminoncol.2015.02.008","volume":"42","author":"B Homet Moreno","year":"2015","unstructured":"Homet Moreno B, Parisi G, Robert L, Ribas A. Anti-PD-1 therapy in melanoma. Semin Oncol. 2015;42:466\u201373.","journal-title":"Semin Oncol"},{"key":"563_CR7","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/j.cell.2015.07.045","volume":"162","author":"JD Wolchok","year":"2015","unstructured":"Wolchok JD. PD-1 blockers. Cell. 2015;162:937.","journal-title":"Cell"},{"key":"563_CR8","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1124\/pr.114.010454","volume":"67","author":"SS Karnik","year":"2015","unstructured":"Karnik SS, Unal H, Kemp JR, Tirupula KC, Eguchi S, Vanderheyden PM, et al. Angiotensin receptors: Interpreters of pathophysiological angiotensinergic stimuli. Pharmacol Rev. 2015;67:754\u2013819.","journal-title":"Pharmacol Rev"},{"key":"563_CR9","doi-asserted-by":"publisher","first-page":"10284","DOI":"10.1073\/pnas.0900351106","volume":"106","author":"DR Rhodes","year":"2009","unstructured":"Rhodes DR, Ateeq B, Cao Q, Tomlins SA, Mehra R, Laxman B, et al. AGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonist. Proc Natl Acad Sci USA. 2009;106:10284\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"563_CR10","doi-asserted-by":"publisher","first-page":"3794","DOI":"10.4161\/cc.8.23.9976","volume":"8","author":"B Ateeq","year":"2009","unstructured":"Ateeq B, Tomlins SA, Chinnaiyan AM. AGTR1 as a therapeutic target in ER-positive and ERBB2-negative breast cancer cases. Cell Cycle. 2009;8:3794\u20135.","journal-title":"Cell Cycle"},{"key":"563_CR11","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.canlet.2012.10.006","volume":"328","author":"X Chen","year":"2013","unstructured":"Chen X, Meng Q, Zhao Y, Liu M, Li D, Yang Y, et al. Angiotensin II type 1 receptor antagonists inhibit cell proliferation and angiogenesis in breast cancer. Cancer Lett. 2013;328:318\u201324.","journal-title":"Cancer Lett"},{"key":"563_CR12","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1002\/iub.1342","volume":"67","author":"R Guo","year":"2015","unstructured":"Guo R, Gu J, Zhang Z, Wang Y, Gu C. MicroRNA-410 functions as a tumor suppressor by targeting angiotensin II type 1 receptor in pancreatic cancer. IUBMB Life. 2015;67:42\u201353.","journal-title":"IUBMB Life"},{"key":"563_CR13","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s00280-009-1136-0","volume":"66","author":"AH Otake","year":"2010","unstructured":"Otake AH, Mattar AL, Freitas HC, Machado CM, Nonogaki S, Fujihara CK, et al. Inhibition of angiotensin II receptor 1 limits tumor-associated angiogenesis and attenuates growth of murine melanoma. Cancer Chemother Pharmacol. 2010;66:79\u201387.","journal-title":"Cancer Chemother Pharmacol"},{"key":"563_CR14","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1038\/bjc.2015.240","volume":"113","author":"IM Reis","year":"2015","unstructured":"Reis IM, Ramachandran K, Speer C, Gordian E, Singal R. Serum GADD45a methylation is a useful biomarker to distinguish benign vs malignant prostate disease. Br J Cancer. 2015;113:460\u20138.","journal-title":"Br J Cancer"},{"key":"563_CR15","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2011","unstructured":"Hodi FS, O\u2019Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2011;363:711\u201323.","journal-title":"N Engl J Med"},{"key":"563_CR16","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1038\/jid.2012.493","volume":"133","author":"C Lo Nigro","year":"2013","unstructured":"Lo Nigro C, Wang H, McHugh A, Lattanzio L, Matin R, Harwood C, et al. Methylated tissue factor pathway inhibitor 2 (TFPI2) DNA in serum is a biomarker of metastatic melanoma. J Invest Dermatol. 2013;133:1278\u201385.","journal-title":"J Invest Dermatol"},{"key":"563_CR17","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1038\/jid.2012.36","volume":"132","author":"S Hoshimoto","year":"2012","unstructured":"Hoshimoto S, Kuo CT, Chong KK, Takeshima TL, Takei Y, Li MW, et al. AIM1 and LINE-1 epigenetic aberrations in tumor and serum relate to melanoma progression and disease outcome. J Invest Dermatol. 2012;132:1689\u201397.","journal-title":"J Invest Dermatol"},{"key":"563_CR18","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1586\/14737159.2014.928204","volume":"14","author":"E Hatzimichael","year":"2014","unstructured":"Hatzimichael E, Syed N, Lo Nigro C, Rao B, Crook T. How detection of epigenetic alterations of blood-borne DNA could improve melanoma diagnosis. Expert Rev Mol Diagn. 2014;14:639\u201342.","journal-title":"Expert Rev Mol Diagn"},{"key":"563_CR19","doi-asserted-by":"publisher","first-page":"53","DOI":"10.14573\/altex.2010.1.53","volume":"27","author":"D Brunner","year":"2010","unstructured":"Brunner D, Appl H, Pfaller W, Gstraunthaler G. Serum-free cell culture: the serum-free media interactive online database. ALTEX. 2010;27:53\u201362.","journal-title":"ALTEX"},{"key":"563_CR20","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1021\/cb500063y","volume":"9","author":"F Magnani","year":"2014","unstructured":"Magnani F, Pappas CG, Crook T, Magafa V, Cordopatis P, Ishiguro S, et al. Electronic sculpting of ligand-GPCR subtype selectivity: the case of angiotensin II. ACS Chem Biol. 2014;9:1420\u20135.","journal-title":"ACS Chem Biol"},{"key":"563_CR21","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1002\/j.1532-2149.2012.00269.x","volume":"17","author":"U Anand","year":"2013","unstructured":"Anand U, Facer P, Yiangou Y, Sinisi M, Fox M, McCarthy T, et al. Angiotensin II type 2 receptor (AT2R) localization and antagonist-mediated inhibition of capsaicin responses and neurite outgrowth in human and rat sensory neurons. Eur J Pain. 2013;17:1012\u201326.","journal-title":"Eur J Pain"},{"key":"563_CR22","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3390\/healthcare2010027","volume":"2","author":"KA Beaumont","year":"2014","unstructured":"Beaumont KA, Mohana-Koumaran N, Hass NK. Modeling melanoma in vitro and in vivo. Healthcare. 2014;2:27\u201346.","journal-title":"Healthcare"},{"key":"563_CR23","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1111\/j.1755-148X.2010.00693.x","volume":"23","author":"EE Patton","year":"2010","unstructured":"Patton EE, Mitchell DL, Nairn RS. Genetic and environmental melanoma models in fish. Pigment Cell Melanoma Res. 2010;23:314\u201337.","journal-title":"Pigment Cell Melanoma Res"},{"key":"563_CR24","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1111\/j.1468-1331.2012.03766.x","volume":"19","author":"AF Carpentier","year":"2012","unstructured":"Carpentier AF, Ferrari D, Bailon O, Ursu R, Banissi C, Dubessy AL, et al. Steroid-sparing effects of angiotensin-II inhibitors in glioblastoma patients. Eur J Neurol. 2012;19:1337\u201342.","journal-title":"Eur J Neurol"},{"key":"563_CR25","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/ncb1137","volume":"6","author":"Y Zou","year":"2004","unstructured":"Zou Y, Akazawa H, Qin Y, Sano M, Takano H, Minamino T, et al. Mechanical stress activates angiotensin II type 1 receptor without the involvement of angiotensin II. Nat Cell Biol. 2004;6:499\u2013506.","journal-title":"Nat Cell Biol"},{"key":"563_CR26","doi-asserted-by":"publisher","first-page":"18237","DOI":"10.1074\/jbc.M500639200","volume":"280","author":"S Miura","year":"2005","unstructured":"Miura S, Karnik SS, Saku K. Constitutively active homo-oligomeric angiotensin II type 2 receptor induces cell signalling independent of receptor conformation and ligand stimulation. J Biol Chem. 2005;280:18237\u201344.","journal-title":"J Biol Chem"},{"key":"563_CR27","doi-asserted-by":"publisher","first-page":"439","DOI":"10.2147\/JPR.S128520","volume":"10","author":"JMK Hesselink","year":"2017","unstructured":"Hesselink JMK, Schatman ME. EMA401: an old antagonist of the AT2R for a new indication in neuropathic pain. J Pain Res. 2017;10:439\u201343.","journal-title":"J Pain Res"},{"issue":"Suppl","key":"563_CR28","doi-asserted-by":"publisher","first-page":"S125","DOI":"10.1111\/j.1440-1681.1996.tb03073.x","volume":"3","author":"DJ Campbell","year":"1996","unstructured":"Campbell DJ. Endogenous angiotensin II levels and the mechanism of action of angiotensin-converting enzyme inhibitors and angiotensin receptor type 1 antagonists. Clin Exp Pharmacol Physiol. 1996;3(Suppl):S125\u201331.","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"563_CR29","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1161\/hy0102.102293","volume":"39","author":"J1 Nussberger","year":"2002","unstructured":"Nussberger J1, Wuerzner G, Jensen C, Brunner HR. Angiotensin II suppression in humans by the orally active renin inhibitor aliskiren (SPP100): comparison with enalapril. Hypertension. 2002;39:E1\u20138.","journal-title":"Hypertension"},{"key":"563_CR30","doi-asserted-by":"publisher","first-page":"E1073","DOI":"10.1503\/cmaj.101497","volume":"183","author":"C Yoon","year":"2011","unstructured":"Yoon C, Yang HS, Jeon I, Chang Y, Park SM. Use of angiotensin-converting-enzyme inhibitors or angiotensin-receptor blockers and cancer risk: a meta-analysis of observational studies. CMAJ. 2011;183:E1073\u201384.","journal-title":"CMAJ"},{"key":"563_CR31","doi-asserted-by":"publisher","first-page":"e189","DOI":"10.1016\/j.cllc.2015.05.002","volume":"16","author":"J Bar","year":"2015","unstructured":"Bar J, Ding K, Zhao H, Han L, Laurie SA, Seymour L. et al. Angiotensin-converting enzyme and aldosterone serum levels as prognostic and predictive biomarkers for cediranib in NCIC Clinical Trials Group Study BR.24. Clin Lung Cancer. 2015;16:e189\u2013201.","journal-title":"Clin Lung Cancer"},{"key":"563_CR32","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1111\/eci.12557","volume":"45","author":"D Moreno-Mu\u00f1oz","year":"2015","unstructured":"Moreno-Mu\u00f1oz D, de la Ha ba-Rodr\u00edguez JR, Conde F, L\u00f3pez-S\u00e1nchez LM, Valverde A, Hern\u00e1ndez V. et al. Genetic variants in the renin-angiotensin system predict response to bevacizumab in cancer patients. Eur J Clin Invest. 2015;45:1325\u201332.","journal-title":"Eur J Clin Invest"},{"key":"563_CR33","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1182\/blood-2005-03-1194","volume":"107","author":"N Syed","year":"2006","unstructured":"Syed N, Smith P, Sullivan A, Spender LC, Dyer M, Karran L. et al. Transcriptional silencing of Polo-like kinase 2 (SNK\/PLK2) is a frequent event in B-cell malignancies. Blood. 2006;107:250\u20136.","journal-title":"Blood"},{"key":"563_CR34","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1038\/sj.bjc.6605042","volume":"100","author":"R Shah","year":"2009","unstructured":"Shah R, Smith P, Purdie C, Quinlan P, Baker L, Aman P. et al. The prolyl 3-hydroxylases P3H2 and P3H3 are novel targets for epigenetic silencing in breast cancer. Br J Cancer. 2009;100:1687\u201396.","journal-title":"Br J Cancer"},{"key":"563_CR35","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1111\/j.1365-2141.2011.08661.x","volume":"15","author":"DP Corkery","year":"2011","unstructured":"Corkery DP, Dellaire G, Berman JN. Leukaemia xenotransplantation in zebrafish\u2014chemotherapy response assay in vivo. Br J Haematol. 2011;15:786\u20139.","journal-title":"Br J Haematol"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41388-018-0563-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41388-018-0563-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41388-018-0563-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:14:26Z","timestamp":1684617266000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-018-0563-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,26]]},"references-count":35,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["563"],"URL":"https:\/\/doi.org\/10.1038\/s41388-018-0563-y","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,26]]},"assertion":[{"value":"28 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}